Daptomycin versus Glycopeptides for the Treatment of Enterococcus faecium Bacteraemia

Background: Ampicillin resistant and glycopeptide susceptible Enterococcus faecium bloodstream infection (GSEF-BSI) incidence has risen. However, the treatment of choice remains unknown. Daptomycin use for the treatment of enterococcal infections has increased, despite effectiveness and safety conce...

Full description

Bibliographic Details
Authors: Echeverría-Esnal, Daniel|||0000-0003-4975-8798, Sorlí, Luisa|||0000-0001-9562-514X, Prim, Núria|||0000-0002-5283-0917, Martin-Ontiyuelo, Clara, Horcajada, Juan Pablo|||0000-0001-9873-5459, Grau, Santiago|||0000-0002-8428-1836
Format: article
Publication Date:2021
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:English
OAI Identifier:oai:ddd.uab.cat:256427
Online Access:https://ddd.uab.cat/record/256427
https://dx.doi.org/urn:doi:10.3390/antibiotics10060716
Access Level:Open access
Keyword:Enterococcus faecium
Bloodstream infection
Bacteraemia
Daptomycin
Glycopeptides
Vancomycin
id ES_cec86cd80e442ef5d5ad7e31a467d413
oai_identifier_str oai:ddd.uab.cat:256427
network_acronym_str ES
network_name_str España
repository_id_str
spelling Daptomycin versus Glycopeptides for the Treatment of Enterococcus faecium BacteraemiaA Cohort StudyEcheverría-Esnal, Daniel|||0000-0003-4975-8798Sorlí, Luisa|||0000-0001-9562-514XPrim, Núria|||0000-0002-5283-0917Martin-Ontiyuelo, ClaraHorcajada, Juan Pablo|||0000-0001-9873-5459Grau, Santiago|||0000-0002-8428-1836Enterococcus faeciumBloodstream infectionBacteraemiaDaptomycinGlycopeptidesVancomycinBackground: Ampicillin resistant and glycopeptide susceptible Enterococcus faecium bloodstream infection (GSEF-BSI) incidence has risen. However, the treatment of choice remains unknown. Daptomycin use for the treatment of enterococcal infections has increased, despite effectiveness and safety concerns. The objective was to compare the effectiveness and safety of daptomycin and glycopeptides in the treatment of GSEF-BSI. Methods: This was a single-centre, retrospective observational cohort study performed at Hospital del Mar (Barcelona, Spain), from January 2006-May 2018. The primary outcome was clinical cure at the end of the therapy, and secondary outcomes included 14-day, 30-day, in-hospital mortality, and length of stay. Results: From a total of 192 patients with GSEF-BSI, 54 (28.1%) were treated with glycopeptides and 17 (8.9%) with daptomycin. Patients treated with daptomycin presented a lower clinical cure than patients treated with glycopeptides (58.8% vs. 83.3%, RR 0.416 (95% CI 0.189-0.915)). After controlling for confounding variables by means of multivariate analysis the significative difference was confirmed (aOR 4.313, 95% CI, 1.053-17.660). The need for treatment discontinuation due to adverse events was similar. Conclusions: Patients with GSEF-BSI treated with glycopeptides showed a higher clinical cure than those treated with daptomycin. 22021-01-0120212021-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/256427https://dx.doi.org/urn:doi:10.3390/antibiotics10060716reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:2564272026-06-06T12:50:31Z
dc.title.none.fl_str_mv Daptomycin versus Glycopeptides for the Treatment of Enterococcus faecium Bacteraemia
A Cohort Study
title Daptomycin versus Glycopeptides for the Treatment of Enterococcus faecium Bacteraemia
spellingShingle Daptomycin versus Glycopeptides for the Treatment of Enterococcus faecium Bacteraemia
Echeverría-Esnal, Daniel|||0000-0003-4975-8798
Enterococcus faecium
Bloodstream infection
Bacteraemia
Daptomycin
Glycopeptides
Vancomycin
title_short Daptomycin versus Glycopeptides for the Treatment of Enterococcus faecium Bacteraemia
title_full Daptomycin versus Glycopeptides for the Treatment of Enterococcus faecium Bacteraemia
title_fullStr Daptomycin versus Glycopeptides for the Treatment of Enterococcus faecium Bacteraemia
title_full_unstemmed Daptomycin versus Glycopeptides for the Treatment of Enterococcus faecium Bacteraemia
title_sort Daptomycin versus Glycopeptides for the Treatment of Enterococcus faecium Bacteraemia
dc.creator.none.fl_str_mv Echeverría-Esnal, Daniel|||0000-0003-4975-8798
Sorlí, Luisa|||0000-0001-9562-514X
Prim, Núria|||0000-0002-5283-0917
Martin-Ontiyuelo, Clara
Horcajada, Juan Pablo|||0000-0001-9873-5459
Grau, Santiago|||0000-0002-8428-1836
author Echeverría-Esnal, Daniel|||0000-0003-4975-8798
author_facet Echeverría-Esnal, Daniel|||0000-0003-4975-8798
Sorlí, Luisa|||0000-0001-9562-514X
Prim, Núria|||0000-0002-5283-0917
Martin-Ontiyuelo, Clara
Horcajada, Juan Pablo|||0000-0001-9873-5459
Grau, Santiago|||0000-0002-8428-1836
author_role author
author2 Sorlí, Luisa|||0000-0001-9562-514X
Prim, Núria|||0000-0002-5283-0917
Martin-Ontiyuelo, Clara
Horcajada, Juan Pablo|||0000-0001-9873-5459
Grau, Santiago|||0000-0002-8428-1836
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Enterococcus faecium
Bloodstream infection
Bacteraemia
Daptomycin
Glycopeptides
Vancomycin
topic Enterococcus faecium
Bloodstream infection
Bacteraemia
Daptomycin
Glycopeptides
Vancomycin
description Background: Ampicillin resistant and glycopeptide susceptible Enterococcus faecium bloodstream infection (GSEF-BSI) incidence has risen. However, the treatment of choice remains unknown. Daptomycin use for the treatment of enterococcal infections has increased, despite effectiveness and safety concerns. The objective was to compare the effectiveness and safety of daptomycin and glycopeptides in the treatment of GSEF-BSI. Methods: This was a single-centre, retrospective observational cohort study performed at Hospital del Mar (Barcelona, Spain), from January 2006-May 2018. The primary outcome was clinical cure at the end of the therapy, and secondary outcomes included 14-day, 30-day, in-hospital mortality, and length of stay. Results: From a total of 192 patients with GSEF-BSI, 54 (28.1%) were treated with glycopeptides and 17 (8.9%) with daptomycin. Patients treated with daptomycin presented a lower clinical cure than patients treated with glycopeptides (58.8% vs. 83.3%, RR 0.416 (95% CI 0.189-0.915)). After controlling for confounding variables by means of multivariate analysis the significative difference was confirmed (aOR 4.313, 95% CI, 1.053-17.660). The need for treatment discontinuation due to adverse events was similar. Conclusions: Patients with GSEF-BSI treated with glycopeptides showed a higher clinical cure than those treated with daptomycin.
publishDate 2021
dc.date.none.fl_str_mv 2
2021-01-01
2021
2021-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/256427
https://dx.doi.org/urn:doi:10.3390/antibiotics10060716
url https://ddd.uab.cat/record/256427
https://dx.doi.org/urn:doi:10.3390/antibiotics10060716
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869420022485483520
score 15,300719

Similar Items